131 related articles for article (PubMed ID: 31101747)
1. First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.
Ahmed Z; Davaro E; Batanian J; Verma N
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31101747
[TBL] [Abstract][Full Text] [Related]
2. Medical ethics collides with public policy: LVAD for a patient with leukemia.
McCarthy PM; Lamm RD; Sade RM
Ann Thorac Surg; 2005 Sep; 80(3):793-8. PubMed ID: 16122431
[No Abstract] [Full Text] [Related]
3. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
4. Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin.
Peña M; Serra J; Ribera JM
Med Clin (Barc); 2018 Dec; 151(12):506-507. PubMed ID: 29731139
[No Abstract] [Full Text] [Related]
5. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Anderlini P; Benjamin RS; Wong FC; Kantarjian HM; Andreeff M; Kornblau SM; O'Brien S; Mackay B; Ewer MS; Pierce SA
J Clin Oncol; 1995 Nov; 13(11):2827-34. PubMed ID: 7595745
[TBL] [Abstract][Full Text] [Related]
6. The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemia.
Yang SC; Chuang MH; Li DK
Br J Clin Pharmacol; 2010 Feb; 69(2):209-11. PubMed ID: 20233187
[No Abstract] [Full Text] [Related]
7. The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Kobayashi T; Ichikawa M; Nannya Y; Kurokawa M
Jpn J Clin Oncol; 2013 Oct; 43(10):1047-51. PubMed ID: 23956441
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Lee MH; Kim SY
Leuk Lymphoma; 2016 Oct; 57(10):2268-74. PubMed ID: 26750985
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
10. 3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Creutzig U; Körholz D; Niemeyer CM; Kabisch K; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
Leukemia; 2000 Feb; 14(2):340-2. PubMed ID: 10673757
[No Abstract] [Full Text] [Related]
11. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
12. Idarubicin administered during pregnancy: its effects on the fetus.
Matsuo K; Shimoya K; Ueda S; Wada K; Koyama M; Murata Y
Gynecol Obstet Invest; 2004; 58(4):186-8. PubMed ID: 15256824
[TBL] [Abstract][Full Text] [Related]
13. Escalated anthracycline dose in adult AML.
Balakrishnan VS
Lancet Oncol; 2017 May; 18(5):e253. PubMed ID: 28416149
[No Abstract] [Full Text] [Related]
14. Miliaria-rash after neutropenic fever and induction chemotherapy for acute myelogenous leukemia.
Nguyen TA; Ortega-Loayza AG; Stevens MP
An Bras Dermatol; 2011; 86(4 Suppl 1):S104-6. PubMed ID: 22068785
[TBL] [Abstract][Full Text] [Related]
15. The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia.
Di Paolo M; Aimo A; Barison A; Aquaro GD; Roas L; Emdin M
Int J Cardiol; 2016 Jan; 203():997-9. PubMed ID: 26625329
[No Abstract] [Full Text] [Related]
16. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of acute myelogenous leukemia complicated with fatal gastrointestinal tract bleeding after treatment with idarubicin and cytarabine].
Nagashima T; Izumi T; Muroi K; Miyasato A; Uchida M; Imagawa S; Komatsu N; Yoshida M; Hatake K; Miura Y; Ozawa K
Gan To Kagaku Ryoho; 2000 Mar; 27(3):487-90. PubMed ID: 10740646
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin oral: new formulation. No proven benefit over 60.
Prescrire Int; 2000 Aug; 9(48):103-5. PubMed ID: 11067717
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin-induced pigmentary changes of the nails.
Borecky DJ; Stephenson JJ; Keeling JH; Vukelja SJ
Cutis; 1997 Apr; 59(4):203-4. PubMed ID: 9104543
[TBL] [Abstract][Full Text] [Related]
20. Subacute anthracycline cardiotoxicity.
Hengel CL; Russell PA; Gould PA; Kaye DM
Heart Lung Circ; 2006 Feb; 15(1):59-61. PubMed ID: 16473794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
